Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Recent headlines cited better-than-expected fiscal Q1 results and a raised revenue outlook, supported by cardiac, diabetes and robotic-surgery products. MDT gained 8.3% over 21 sessions and closed at a period high of $94.42 on September 4.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Cash Flow ⢠Solid Liquidity ⢠Elevated Leverage Medtronic delivers resilient margins, strong cash flow and liquidity, but moderate returns, sizable debt/intangible exposure, and an above-historical valuation warrant caution.
Price Behavior
Key Price Behavior Insights: ⢠Strong monthly rise ⢠Near key resistance ⢠Support remains firm Support Level: $92.00; $90.60â$91.20 Resistance Level: $94.17â$95.00 MDT gained 8% over the last month and remains bullish above support, but a breakout above $94.17â$95.00 is needed to sustain upside while a drop below $92.00 would weaken momentum.
Sentiment & News
Key News Insights: ⢠Guidance raised ⢠Growth platforms ⢠Tariff risks Medtronic beat Q1 estimates and raised FY2027 guidance, driven by growth platforms despite tariff and currency risks.
AI Summary
Medtronic's raised growth outlook and cardiovascular-led momentum support a re-rating from defensive slow grower to credible growth story, but investors should favor the stock only if ablation, renal denervation, and robotics investments translate into sustained share gains and ROIC above its current ~12% level.
Description
Medtronic plc is a global medical device company that develops, manufactures and sells device-based therapies to hospitals, clinicians and patients. Its operating structure encompasses cardiovascular products (including implantable cardiac devices, valve and endovascular therapies, and remote monitoring software), a broad surgical portfolio covering stapling, energy and robotic-assisted systems as well as diagnostic and ventilation therapies, neuroscience products for spine and neurovascular care with intraoperative imaging and guidance systems, and diabetes care devices such as insulin delivery and glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Sep 4 | Sep 11 | MDT | Medtronic plc | Recent headlines cited better-than-expected fiscal Q1 results and a raised revenue outlook, supported by cardiac, diabetes and robotic-surgery products. MDT gained 8.3% over 21 sessions and closed at a period high of $94.42 on September 4. | Active | +0.0% |